|NASDAQ: GLYC||Healthcare / Biotechnology / USA|
|1.26||+0.0100||+0.80%||Vol 469.62K||1Y Perf 9.65%|
|Mar 31st, 2023 16:00 DELAYED|
|- -||-0.06 -4.76%|
|Target Price||8.00||Analyst Rating||Strong Buy 1.00|
|Potential %||534.92||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-100/-50||Value Ranking||★★+ 49.53|
|Insiders Value % 3/6/12 mo.||-/-100/80||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/65||Income Ranking||— -|
|Price Range Ratio 52W %||20.55||Earnings Rating||Strong Buy|
|Market Cap||80.95M||Earnings Date||27th Apr 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Apr 2023|
|Estimated EPS Next Report||-0.16|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||428.13K|
|Avg. Monthly Volume||561.98K|
|Avg. Quarterly Volume||1.44M|
GlycoMimetics Inc. (NASDAQ: GLYC) stock closed at 1.26 per share at the end of the most recent trading day (a 0.8% change compared to the prior day closing price) with a volume of 469.62K shares and market capitalization of 80.95M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 57 people. GlycoMimetics Inc. CEO is Rachel K. King.
The one-year performance of GlycoMimetics Inc. stock is 9.65%, while year-to-date (YTD) performance is -58.42%. GLYC stock has a five-year performance of -92.24%. Its 52-week range is between 0.51 and 4.16, which gives GLYC stock a 52-week price range ratio of 20.55%
GlycoMimetics Inc. currently has a PE ratio of -2.80, a price-to-book (PB) ratio of 3.08, a price-to-sale (PS) ratio of 1 943.18, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -73.09%, a ROC of -73.24% and a ROE of -82.92%. The company’s profit margin is -%, its EBITDA margin is -58 282.60%, and its revenue ttm is $75.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from GlycoMimetics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. GlycoMimetics Inc.’s next earnings report date is 27th Apr 2023.
The consensus rating of Wall Street analysts for GlycoMimetics Inc. is Strong Buy (1), with a target price of $8, which is +534.92% compared to the current price. The earnings rating for GlycoMimetics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
GlycoMimetics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
GlycoMimetics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.67, ATR14 : 0.15, CCI20 : -166.72, Chaikin Money Flow : -0.09, MACD : -0.19, Money Flow Index : 23.57, ROC : -15.44, RSI : 34.36, STOCH (14,3) : 22.50, STOCH RSI : 0.12, UO : 48.47, Williams %R : -77.50), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of GlycoMimetics Inc. in the last 12-months were: Armand Girard (Buy at a value of $6 825), Brian M. Hahn (Buy at a value of $21 200), Daniel M. Junius (Buy at a value of $37 400), Edwin Rock (Buy at a value of $556 500), Harout Semerjian (Buy at a value of $32 250), John L. Magnani (Buy at a value of $52 703), Sandell D Scott (Sold 4 050 149 shares of value $12 670 400 ), Scott Koenig (Option Excercise at a value of $26 775), Timothy R. Pearson (Buy at a value of $25 026)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
CEO: Rachel K. King
Telephone: +1 240 243-1201
Address: 9708 Medical Center Drive, Rockville 20850, MD, US
Number of employees: 57
Fri, 10 Mar 2023 22:08 GMT GlycoMimetics considers SVB exposure immaterial- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.